AC Immune SA SMA 50
What is the SMA 50 of AC Immune SA?
The SMA 50 of AC Immune SA is $3 -14.06%
What is the definition of SMA 50?
SMA 50 is an average stock price from the last 50 days calculated as an unweighted mean of the previous 50 stock closing prices.
Simple moving average of 50 days for a stock is an unweighted moving average over the past 50 days. Moving averages will always exhibit a lag and the longer the period used for averaging the greater the lag will be. Because of the large amounts of data considered when calculating a long-term moving average, it takes a considerable amount of movement in the market to cause the moving average to change its course.
Using a moving average to confirm a trend in price is one of the most basic, yet effecting ways of using the indicator. Moving averages take into account what has already happened and a whole range of past events, which makes them such a good technical analysis tool for trend confirmations. Generally, a long-term moving average that is clearly on the upswing is a confirmation of a bullish trend. Conversely, a long-term moving average that is clearly on the downswing is a confirmation of a bearish trend.
SMA 50 of companies in the Health Care sector on NASDAQ compared to AC Immune SA
What does AC Immune SA do?
ac immune is a clinical-stage swiss-based biopharmaceutical company, listed on nasdaq, which aims to become a global leader in precision medicine for neurodegenerative diseases. the company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins. ac immune’s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as alzheimer’s disease (ad). the company’s pipeline features nine therapeutic and three diagnostic product candidates – with five product candidates currently in clinical trials. the most advanced of these is crenezumab, a humanized anti-amyloid-β monoclonal igg4 antibody that targets monomeric and aggregated forms of amyloid-β, with highest affinity for neurotoxic oligomers. crenezumab is currently in two phase 3 clinical studies for ad, under a global program conducted by the collabor
Companies with sma 50 similar to AC Immune SA
- THL Credit has SMA 50 of $3 +3.46%
- Impex Ferro Tech has SMA 50 of ₨3 +8.27%
- Weiqiao Textile has SMA 50 of HKD$3 +0.07%
- Dare Bioscience Inc has SMA 50 of $3 -7.03%
- Red Lion Hotels has SMA 50 of $3 +0.00%
- APN Convenience Retail REIT has SMA 50 of AUD$3 +0.00%
- AC Immune SA has SMA 50 of $3 -14.06%
- Haitong Securities Co has SMA 50 of HKD$3 +4.61%
- Avalon GloboCare has SMA 50 of $3 -564.58%
- Vistagen Therapeutics has SMA 50 of $3 -10.95%
- Gran Colombia Gold has SMA 50 of CAD$3 -12.38%
- Avalon GloboCare has SMA 50 of $3 -564.58%
- Alps Industries has SMA 50 of ₨3 +4.66%